Search Results - "Iorga, Şerban R."

Erratum to ‘Lipid Treatment and Goal Attainment Characteristics among Persons with Atherosclerotic Cardiovascular Disease in the United States’ [American Journal of Preventive Cardiology 1C (2020) 100010] by Klimchak, Alexa C., Patel, Miraj Y., Iorga, Şerban R., Kulkarni, Natasha, Wong, Nathan D.

Get full text

Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany by März, Winfried, Dippel, Franz-Werner, Theobald, Karlheinz, Gorcyca, Katherine, Iorga, Şerban R., Ansell, David

“…Elevated low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for cardiovascular (CV) events. European guidelines recommend reducing LDL-C as…”
Get full text

Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan by Furst, Daniel E., Amato, Anthony A., Iorga, Şerban R., Gajria, Kavita, Fernandes, Ancilla W.

“…Introduction: Idiopathic inflammatory myopathies have a reported incidence of 0.1 to 1 per 100,000 person‐years and prevalence of 0.55 to 6 per 100,000 in the…”
Get full text

A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease by Zaidi, Ahmar U, Glaros, Alexander K, Lee, Soyon, Wang, Taiji, Bhojwani, Rhea, Morris, Eric, Donohue, Breanne, Paulose, Jincy, Iorga, Åerban R, Nellesen, Dave

“…Abstract Background and purpose Sickle cell disease (SCD) is a collection of rare inherited blood disorders affecting approximately 100,000 people in the U.S…”
Get full text

Lifetime Costs for Treated Follicular Lymphoma Patients in the US by Eichten, Caitlin, Ma, Qiufei, Delea, Thomas E., Hagiwara, May, Ramos, Roberto, Iorga, Şerban R., Zhang, Jie, Maziarz, Richard T.

“…Background and Objective The objective of this study was to estimate the lifetime costs of patients receiving treatment for follicular lymphoma (FL) in the…”
Get full text

Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice by Arca, Marcello, Ansell, David, Averna, Maurizio, Fanelli, Francesca, Gorcyca, Katherine, Iorga, Şerban R., Maggioni, Aldo P., Paizis, Georges, Tomic, Radovan, Catapano, Alberico L.

“…Statin utilization and lipid goal achievement were estimated in a large sample of Italian patients at high/very-high cardiovascular (CV) risk. Patients aged…”
Get full text

Lipid-lowering Therapy and Goal Achievement in High-risk Patients From French General Practice by Ferrières, Jean, Gorcyca, Katherine, Iorga, Şerban R., Ansell, David, Steen, Dylan L.

“…The goal of this study was to summarize patterns of lipid-lowering therapy (LLT) usage and achievement of guideline-identified lipid goals in a 2015 general…”
Get full text

Healthcare Resource Utilization and Costs Associated with Autosomal Dominant Polycystic Kidney Disease by Blanchette, Christopher M., Iorga, Şerban R., Altan, Aylin, Seare, Jerry G., Fan, Ying, Rossetti, Sandro, Gutierrez, Benjamin

“…Background: Autosomal dominant polycystic kidney disease (ADPKD), a hereditary nephropathy, eventually leads to end-stage renal disease (ESRD), typically by…”
Get full text

Epidemiology of Systemic Sclerosis in a Large US Managed Care Population by FURST, Daniel E, FERNANDES, Ancilla W, IORGA, Serban R, GRETH, Warren, BANCROFT, Tim

“…To estimate the incidence and prevalence of systemic sclerosis (SSc) in a large US managed care organization (MCO) database. Subjects with claims-based…”
Get full text

Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States by Klimchak, Alexa C., Patel, Miraj Y., Iorga, Şerban R., Kulkarni, Natasha, Wong, Nathan D.

“…National estimates of atherosclerotic cardiovascular disease (ASCVD) in the United States (US) are scarce, especially for patients grouped by cardiovascular…”
Get full text

Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002–2016 by Romanelli, Robert J., Ito, Matthew K., Karalis, Dean G., Huang, Hsiao-Ching, Iorga, Şerban R., Kam, Ivy W., Thompson, Stephen, Azar, Kristen M.J.

“…A better understanding of patterns in statin utilization and low-density lipoprotein cholesterol (LDL-C) among patients with atherosclerotic cardiovascular…”
Get full text

Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population by Furst, Daniel E., Amato, Anthony A., Iorga, Şerban R., Bancroft, Tim, Fernandes, Ancilla W.

“…Introduction: In this study we determined the health‐care costs and resource utilization associated with idiopathic inflammatory myopathies (IIMs) in a large…”
Get full text

Preadmission glycemic control and changes to diabetes mellitus treatment regimen after hospitalization by Bergenstal, Richard M, Fahrbach, Jessie L, Iorga, Şerban R, Fan, Ying, Foster, Shonda A

“…To evaluate treatment patterns associated with diabetes medication regimen changes after hospitalization on the basis on preadmission hemoglobin A1c levels. In…”
Get more information

Long-term clinical and economic outcomes associated with angiotensin II receptor blocker use in hypertensive patients by Swindle, Jason P., Buzinec, Paul, Iorga, erban R., Ramaswamy, Krishnan, Panjabi, Sumeet

“…Abstract Objective: To examine clinical and economic outcomes associated with angiotensin II receptor blockers (ARB). Methods: Retrospective claims data were…”
Get full text

The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients by Sikirica, Mirko, Iorga, Serban R, Bancroft, Tim, Potash, Jesse

“…Pulmonary arterial hypertension (PAH) is a rare condition that can ultimately lead to right heart failure and death. In this study we estimated the health care…”
Get full text

CONSISTENT LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING EFFICACY OF ALIROCUMAB IN HIGH AND VERY HIGH CARDIOVASCULAR RISK PATIENTS WITH LOW-DENSITY LIPOPROTEIN CHOLESTEROL >100/70 MG/DL AT BASELINE by Robinson, Jennifer, Schiele, Francois, Laufs, Ulrich, Lettino, Maddalena, Valcheva, Velichka, Guillonneau, Sophie, Iorga, Serban R, Narcisse, Nadège, Fox, Keith

“…Background: People at particularly high risk of atherosclerotic cardiovascular disease (ASCVD) with uncontrolled low-density lipoprotein cholesterol (LDL-C)…”
Get full text

Annual Medical Costs and Healthcare Resource Use in Patients with Systemic Sclerosis in an Insured Population by FURST, Daniel E, FERNANDES, Ancilla W, IORGA, Serban R, GRETH, Warren, BANCROFT, Tim

“…Systemic sclerosis (SSc) is a chronic autoimmune disease. The objective of our study was to estimate the medical costs and healthcare resource use of subjects…”
Get full text

Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population by Furst, Daniel E, Clarke, Ann, Fernandes, Ancilla W, Bancroft, Tim, Gajria, Kavita, Greth, Warren, Iorga, Serban R

“…Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organ systems, including the kidneys (lupus nephritis) and the…”
Get more information

Abstract P128: Statin Prescribing, Switching, and Low-density Lipoprotein Cholesterol Goal Attainment Across Racial/Ethnic Groups With Atherosclerotic Cardiovascular Disease by Romanelli, Robert J, Ito, Matthew J, Karalis, Dean G, Huang, Hsiao- Ching, Iorga, Serban R, Kam, Ivy, Thompson, Stephen F, Azar, Kristen M

“…Abstract only Introduction: Statins are effective in reducing low-density lipoprotein cholesterol (LDL-C) and preventing cardiovascular (CV) events in patients…”
Get full text

Abstract 348: Marked Variability in the Patterns of Care and Health Outcomes among Patients Evaluated for Suspected Obstructive Coronary Artery Disease: Results from a Healthcare Claims Database Study of 12,129 Patients by Ladapo, Joseph, Seare, Jerry G, Iorga, Serban R, Buzinec, Paul N, Monane, Mark

“…Abstract only Introduction: Over 10 million low-risk, non-diabetic Americans with signs and symptoms of suspected obstructive CAD undergo diagnostic testing,…”
Get full text